Lipiclair

Fenofibrate, the active ingredient in Lipiclair, is a fibrate presented as an oral tablet for oral use. It treats hypertriglyceridemia, mixed dyslipidemia and primary hypercholesterolemia as adjunct therapy in adults.

GNH USA supplies Lipiclair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipiclair (fenofibrate) acts on lipid metabolism disorders to improve blood lipid profiles.

Hypertriglyceridemia: lowers elevated triglyceride levels. Mixed dyslipidemia: reduces triglycerides and LDL‑cholesterol while increasing HDL‑cholesterol. Primary hypercholesterolemia (adjunct therapy): adds further LDL‑cholesterol reduction when combined with statins.

Common Side Effects: - Gastrointestinal discomfort such as nausea, dyspepsia or abdominal pain. - Headache. - Muscle aches or mild myalgia. - Elevated liver enzymes. - Elevated serum creatinine.

Serious or Rare Side Effects: - Rhabdomyolysis or severe myopathy, especially with statins. - Significant hepatic injury or hepatitis. - Severe hypersensitivity reactions, including skin rash or angioedema. - Acute pancreatitis.

Before initiating therapy, clinicians should consider several safety aspects.

Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. Renal function monitoring: evaluate creatinine clearance, especially in patients with renal impairment. Gallbladder disease assessment: avoid use in patients with active gallstones or biliary obstruction. Muscle symptom vigilance: educate patients to report unexplained muscle pain or weakness. Drug interaction review: check concomitant medications that may increase risk of myopathy. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Fenofibrate may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - High‑dose statins (e.g., rosuvastatin) – increased risk of rhabdomyolysis. - Gemfibrozil – synergistic myopathy risk. - Cyclosporine – elevated fenofibrate plasma levels. - Warfarin – potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Bile‑acid sequestrants – may reduce fenofibrate absorption. - Oral contraceptives – possible alteration of lipid parameters. - Antihypertensive agents – monitor blood pressure changes. - Other lipid‑lowering agents – assess cumulative lipid effects.